New antibody combo aims to flush out hidden HIV

NCT ID NCT07217379

Recruiting now Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two experimental antibodies (MGD014 and MGD020) are safe in people with HIV who are on standard antiretroviral therapy. Some participants also receive a drug called Vorinostat to help expose hidden HIV, or temporarily stop their regular HIV meds. The goal is to see if the antibodies can help control the virus, but participants will need to stay on lifelong HIV treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV (HUMAN IMMUNODEFICIENCY VIRUS)

Contacts and locations

Locations

Kenya Medical Research Institute/Walter Reed Project
NOT_YET_RECRUITING

Kericho, Kenya
Moi University Clinical Research Center
NOT_YET_RECRUITING

Eldoret, Kenya
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.